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S_ary It has been shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) can induce
specific and non-specific anti-tumour cytotoxicity and also stimulates the proliferation and function of
peripheral lymphocytes and thymocytes. GM-CSF and interleukin 2 (IL-2) act synergistically on peripheral
lymphocytes for the induction of a highly effective cytotoxic cell population. Thus, the goal of our investiga-
tion was to study the effects of GM-CSF upon expansion, proliferation and in vitro killing activity of
tumour-infiltrating lymphocytes (TILs) from renal cell carcinoma (RCC). TILs from seven consecutive
tumours were cultured with GM-CSF (500 or 1000 nmol ml1') without IL-2 supplementation, with suboptimal
doses of IL-2 (8 and 40 U ml-') plus GM-CSF (1000 nmol ml-'), and with a dose of IL-2 (400 U ml'- ) which
sufficed alone to induce TIL development plus GM-CSF (500 or 1000 nmol ml-'). GM-CSF alone or together
with suboptimal doses of IL-2 was not able to induce or facilitate TIL development in these cultures. When
GM-CSF at both concentrations studied was added to optimal doses of IL-2 the resulting TIL populations
proliferated significantly better and faster (+ 66%), resulting in a higher cell yield (+ 24%) at the time of
maximal expansion of the TIL cultures. The length of the culture periods of TILs was not affected by
GM-CSF when compared with the control cultures supplemented with IL-2 alone. In vitro killing activity of
TIL populations stimulated with IL-2 and GM-CSF remained unspecific, but lysis of the autologous tumour
targets as well as the allogeneic renal tumour targets was significantly enhanced (+ 138%) as compared with
the corresponding control TILs stimulated with IL-2 alone. Lysis of the natural killer (NK)-sensitive control
cell line K562 and the NK-resistant Daudi cell line remained unchanged even though FACS analysis of TILs
cultured with IL-2 and 1000 nmol of GM-CSF demonstrated a significantly higher proportion of cells
expressing the CD56 molcule (+ 50%). Specific receptors for GM-CSF could not be demonstrated on TILs
from RCC. Our data demonstrate that GM-CSF alters the biological behaviour of IL-2-activated TILs from
renal cell carcinoma in terms of proliferation, in vitro killing activity and cell-surface molecule expression.
Possible clinical implications for adoptive immunotherapy include the use of GM-CSF during the ex vivo
culture period in order to reach higher TIL counts with possibly higher killing activity, as well as the systemic
application of GM-CSF in patients receiving adoptive immunotherapy. Further in vitro and in vivo investiga-
tions seem to be warranted to further elucidate the role of GM-CSF in adoptive immunotherapy.
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Granulocyte-macrophage colony-stimulating factor (GM-
CSF) is a multilineage glycoprotein cytokine which is
synthesised by a variety of cell types, such as T and B
lymphocytes (Chan et al., 1986; Herrmann et al., 1988; Pluz-
nik et al., 1989), macrophages (Thorens et al., 1987; Fibbe et
al., 1988), fibroblasts (Kaushansky et al., 1988) and
endothelial cells (Sieff et al., 1987). Expression of GM-CSF
has also been documented in certain solid tumours (Zinzar et
al., 1985), and myeloid leukaemia cells are also believed to be
a potential pathophysiological source of this cytokine
(Oklamura et al., 1988; Fiedler et al., 1990). We have recently
shown that tumour-infiltrating lymphocytes (TILs) from
renal cell cancer (RCC) are able to release a wide array of
various cytokines, including GM-CSF (Steger et al., 1994).
GM-CSF acts as a potent growth factor both in vitro and in
vivo, stimulating proliferation and maturation of myeloid
progenitor cells, giving rise to neutrophilic and eosinophilic
granulocytes and monocytes (Begley et al., 1988; Lopez et al.,
1986; Metcalf et al., 1986; Silberstein et al., 1986; Kaufman
et al., 1989).
GM-CSF is involved in the host defence mechanisms and
is a potent factor in activating macrophages for tumour cell
killing. Activated macrophages can be non-specifically
cytotoxic for tumour cells in an MHC-independent fashion
(Fidler and Schroit, 1988). They also can specifically recog-
nise tumour cells in vivo, thus playing an important role in
host surveillance against autochthonous transformed neoplas-
tic cells (Fidler, 1985). Vaccination with irradiated tumour
cells engineered to secrete murine GM-CSF has been shown
to induce specific anti-tumour immunity (Dranoff et al.,
1993). TILs from RCC are able to secrete GM-CSF upon
stimulation (Steger et al., 1994), and this ability to secrete
GM-CSF upon autologous tumour stimulation was recently
shown to correlate positively with the clinical response after
TIL immunotherapy in melanoma patients (Schwartzentruber
et al., 1994). In addition, there are reports that GM-CSF can
stimulate proliferation or function of T-cell lines. It has been
demonstrated that GM-CSF can serve as a growth factor for
the IL-2/IL4 dependent T-cell line HT-2, acting through a
pathway which is distinct from that of IL-2 or IL4 (Kupper
et al., 1987; Woods et al., 1987). Herbelin et al. (1989, 1990)
reported that GM-CSF and IL-1 act synergistically to
stimulate thymocyte proliferation via an IL-2-independent
pathway. Santoli et al. (1988) demonstrated that GM-CSF
can support the growth of cells within the lymphoid lineage
and exert potent amplifying effects on IL-2-induced T-cell
growth in vitro. Moreover, in a recent evaluation of GM-
CSF by Masucci et al. (1990), it was demonstrated that
GM-CSF and IL-2 act synergistically on peripheral lym-
phocytes with the induction of a highly effective cytotoxic cell
population.
IL-2-based immunotherapy and adoptive immunotherapy
with in vitro-activated lymphocyte-activated killer (LAK)
cells and TILs are increasingly applied in the therapy of
human solid tumours (Rosenberg et al., 1988; Topalian et al.,
1988). RCC is one of the more extensively investigated
human cancers in which these novel forms of anti-cancer
therapy have shown activity (Belldegrun et al., 1988; Finke et
al., 1988; Alexander et al., 1990; Figlin et al., 1992; Thom-
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pson et al., 1992; Weiss et al., 1992). In recent publications
our group has demonstrated that several cytokines, such as
IL-4 (Tso et al., 1992), IL-6 (Lee et al., 1991) and IL-7
(Ditonno et al., 1992), are able to modulate TILs derived
from RCC under certain culture conditions. This fact sug-
gests that a variety of cytokines, and perhaps growth factors
as well, are involved in the activation of tumour-derived and
specific immunocompetent cells, rather than 1L-2 alone.
Based on the mentioned reports demonstrating some activity
of GM-CSF on T cells, we designed experiments to inves-
tigate the influence of GM-CSF on TILs from RCC. T'he
results ofthese experiments show that GM-CSF, when added
to optimal concentrations of IL-2, has emkarkable modul-
atory effects on the growth, expansion, proliferation and the
in vitro cytolytic activity of RCC TILs. Possible clinical
implications will be discussed.
Mateil and mhos
Lymphocyte cultures
TILs were cultured from the primary tumour of seven
patients with RCC. Tumours were obtained from the
operating room, minced into small pieces and enzymatically
digested overnight in RPMI-1640 culture medium (Celigro,
Mediatech, Washington, DC, USA) containing 0.01%
hyaluronidase type V, 0.002% DNAse type I, 0.1% col-
lanase type IV (Sigma, St Louis, MO, USA), 2mM L-
glutamine (Gibco, Grand Island, NY, USA) and 50 Lgml-'
gentamicin. The resuting sing-cell suspensions were then
passed over single-step Ficoll-Hypaque density gradients
(LSM, Organon Tenika, Durham, NC, USA). The mixture
con ng both TILs and tumour cells rieved from the
gradient interfaces was washed, counted and either cryo-
prsrved for use as targets in cytotoxicity assays or cultured
in six-well tissue culture plates (Costar, Cambridge, MA,
USA, or Falcon, Becton Dickinson Labware, Lincoln Park,
NJ, USA) at a density of 0.5 x 106 cellsml-' in medium
consisting of RPMI-1640 plus 10% heat-inactivated human
AB serum (Irvine Scientific, Santa Ana, CA, USA),
50IUmlI penicillin, 50tg ml ' streptomycin (JHR Bio-
scences, Lenexa, KS, USA) and 2mM L-glutmjn.
Culture conditions
GM-CSF (Sandoz, Basle, Switzrland) at concentrations of
500 nmolml-' and 1000nmolml-' was added to the single-
cell suspensions, either alone or together with various con-
centrations ofinterluin 2 (8, 40, 400 Uml-'; Hoffmann La
Roche, Nutley, NJ, USA; 400 Um1' equals 1000 Cetus U
ml-' or 6000 IU ml-'). TIL cultures supplemeted with the
same concentrations of IL-2 alone served as controls. All cell
cultures were maintained at 37C and 5% carbon dioxide and
passaged as needed to maintain a concentration of 1 x 10' to
1.5x 106 TILsml-.
Proliferation
To determine the proliferation of TIL cultures [3HI1
thymidine uptake assays were performed. AWroximately
5 x 10' TILs per well were cultured for 4 days in 96-well
flat-bottom microtitre plates (Costar) in 100p1 of complete
medium supplmented with GM-CSF and/or IL-2 at concen-
trations cited in the text. Triplicate wells were pulsed with
0.5jCi of [3HJTdR (Dupont, Boston, MA, USA) for 24 h
and then harvested for scintillation counting using a PHD
cell harvter (Cambridge Technology, Cambridge, MA,
USA). The incorporated [3HITdR was measured with a liquid
scintillation counter. Results are presented as mean counts
per min (c.p.m.) + s.d.
Expansion
X-fold expansion of the TIL cultures was caculated by
dividing the number of TILs counted at the time of the
maximal expansion by the number of lymphocytes put in
culture after processing the tumour specimen to single-cell
suspensions.
Phenotypic analysis
Flow cytometric analysis was performed on TILs within
several days of a functional assay. Phenotypic expression of
TILs was determined by two-colour fluorescence. Antibodies
used were: anti-Leu-4 (CD3, pan-T-cel)-FITC + anti-Leu-19
(CD56, NK cells, LAK cells, T-cell subsets)-PE; anti-IL-2
receptor (CD25, activated T cells)-PE; anti-Leu-3a (CD4, T
belper/inducer cells)-FITC + anti-Leu-2a (CD8, T cytotoxic/
T suppresor cells)-PE. All antibodies were purchased from
Becton Dickinson, San Jose, CA, USA. FITC-IgGl and
PE-IgG2a (Simultest Control, Becton Dickinson, San Jose,
CA, USA) were used as negative controls. Approximately
5 x 105 TILs in 50p1 of staining buffer (1 x PBS without
Ca2+ and Mg2+ plus 2% fetal calf serum plus 0.1% sodium
azide, pH 7.3) were incubated with 10pl ofeach antibody for
30min at 4-C. Cells were then washed twice, fixed with 1%
paraformaldehyde and resuspended in 0.5 ml of staining
buffer. Cell-surface antigens were detected using a FACS 440
scan flow cytometer (Becton Dickinson, Mountain View, CA,
USA).
Cytotoxicity assays
The cytotoxic activity of TILs grown in IL-2 and/or GM-
CSF was tested in. vitro in a standard 4 h 5'Cr release assay
against fresh (cryopreserved) autologous tumour, one allo-
geneic tumour target (TU 59), K562, a NK-sensitive eryth-
roleukaemia cell line, and Daudi cells, a NK-resistant
lymphoma. A total of 5 x 107 target cells in a vohlume of2 ml
were labelled with 200pCi of 5'Cr (ICN Radiochemica,
Irvine, CA, USA) for 1 h at 3TC and washed three times
before use. The 5 x 103 targets and the appropriate number
ofeffectors at seveal effector-target (E/T ratios (40:1, 20:1,
10:1 and 5:1) were plated in triplicate in a total of 0.2 ml of
medium in 96-well round-bottom microtitre plates. After a
4 h incubation period the plates were centrifuged at
800 r.p.m. for 3 min and 100p1 of the supernatant was
harvested, and counted on a gamma counter. The percentage
specific lysis was determined as:
Experimental counts - spontaneous counts
Total counts - spontaneous counts
x 100
Target cells incubated in medium alone and with 1%
sodium dodecyl sulphate were used to determine spontaneous
and maximal relase of chromium respectively. Cytotoxicity
is expressed as lytic units (LU) per 1 x 10' cells. One lytic
unit is defined as the number of effector cells needed to lyse
30% of 5 x 103 target cells.
GM-CSFreceptor assays
For the detection of cell-urface receptors specific for GM-
CSF a previously published ligand-binding assay with 1'I-
labelled GM-CSF was used (DiPersio et al., 1988).
Statistical anaysis
The significn of differences in number of lytic units in
assay and differences in percentages ofpositive cells ofFACS
analysis was determined the Wilcoxon signed-rank test
A P-value<0.05 was conside to indicate signia and
two-tailed P-values were used.
Redls
Growth, expansion andproliferation
The results of growth, maximal expansion and days in cul-
ture of TIL cultures under the various culture conditions are
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suboptimal concentrations of IL-2 (8, 40 U ml') failed to
induce TIL growth in all cultures. Adding 500 nmol ml-' or
1000 nmol ml-' GM-CSF to the cell cultures together with a
concentration of IL-2 which was alone sufficient to induce
TIL growth (400 U ml-') resulted in the development of
TILs. The expansion of TILs cultured in IL-2 + GM-CSF
was significantly higher at both concentrations of GM-CSF
when compared with TILs grown in IL-2 alone. The culture
period of all TIL cultures did not differ regardless of the
culture conditions.
The results of the [3HJTdR incorporation assays can be
seen in Table II. TILs incubated with IL-2 and GM-CSF at
both concentrations studied proliferated significantly better
than TILs grown in IL-2 alone.
Cytolytic activity
Four hour 5"Cr-release assays were performed in all seven
TIL populations at an early stage of culture (days 25-45)
and at later stage of culture (days 53-72). Fresh (cryo-
preserved) autologous and the allogeneic renal target cells
(TU 59) were available for all experiments.
At an early stage of culture TILs grown with IL-2 and
GM-CSF showed an enhanced killing activity against the
autologous tumour target as well as against the allogeneic
renal tumour target (Table III). The killing behaviour against
the NK-cell sensitive K562 target and the NK-resistant
Daudi cell target was unchanged when compared with the
killing behaviour of corresponding TIL cultures activated
with IL-2 alone. Killing of all TIL populations tested was
always non-specific, as the allogeneic renal target, K562 and
Daudi cells were lysed equally well or better independently of
the culture condition. The same pattern in killing was
observed at the second evaluation at a later stage of the
cultures (data not shown), and killing remained also non-
specific.
Phenotypical analysis
Phenotypical analysis of TIL cultures (Table IV) sup-
plemented with IL-2 or GM-CSF and IL-2 revealed similar
percentages of cells positive for CD3 and CD3/CD56 respec-
tively. TILs grown with 1000 nmol ml-' GM-CSF and IL-2
showed a significantly higher percentage of CD56+ cells,
while expression of CD56 was unchanged in TILs activated
with 500 nmol ml-' GM-CSF + IL-2 when compared with
TILs activated with IL-2 alone. The percentages of CD8+
and CD4+ cells were similar independent of the culture
conditions. Expression of the IL-2 receptor (CD25) was
unaffected by GM-CSF.
GM-CSF receptor analysis
Two TIL populations were analysed for their ability to exp-
ress the GM-CSF receptor. One population was activated
with IL-2 400 U ml-' alone and the other with IL-2
400Uml' +GM-CSF 100OnmolmlV'. In neither of the
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Table I Effects of GM-CSF on the proliferation of TILs from
RCC
Culture condition (Uml-' nmolml-')
Culture IL-2 IL-2 + GM-CSF IL-2 + GM-CSF
TIL (days) (400) (40X0)/S) (400/1000)
TiL 74 22 27 120 27 681 37 917
TIL 75 20 16433 34601 40 325
TL 76 20 14 233 21 990 21 213
TL 77 18 22 651 30 190 31 457
TL 78 23 15 385 27 341 30 501
TIL 80 21 16 405 19 132 19 514
TL 82 18 17 291 23 477 23 537
Median 16 433 27 341* 30 501*
[3HTrdR (0.5gLCi perwell)incorporation. Values represent the mean
of c.p.m. in triplicate determinations. P<0.02 vs IL-2 control.
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two TIL populations tested could GM-CSF receptors be
detected.
In summary, the addtion of GM-CSF to optimal concen-
trations of IL-2 resulted in a 25% increase in expansion, in a
66% increase in thymidine incorporation and in a 50%
increase in CD56 expression of TILs from RCC. Moreover,
there was a 138% increase in killing capacity of the tested
IL-2/GM-CSF TILs against the autologous and allogeneic
renal tumour targets, while the killing behaviour against the
NK-sensitive cell line K562 and the NK-resistant cell lne
Daudi remained unchanged or tended to be lower.
GM-CSF exerts a wide array of biological actitities on many
cell types. Besides its stimulatory function on the prolifera-
tion of immature progenitors, it was soon recognised that
GM-CSF could also enhance differentiated functions of
mature effector cells (Lopez et al., 1983; Vadas et al., 1983;
Weisbart et al., 1985, 1986). Although still somewhat con-
troversial, some wel-designed in vitro studies have ckarly
demonstrated that the activity of GM-CSF is not resticted
to monocytes/macrophage and granulocytes. Also, the pro-
liferation and growth of T cells (Kupper et al., 1987; Woods
et al., 1987; Santoli et al., 1988; Herbelin et al., 1989, 1990)
as well as their in vitro killing behaviour (Masucci et al.,
1990) can be modulated by GM-CSF.
The first goal of our study was to investigate the ability of
GM-CSF to induce TIL development from single-:ell suspen-
sions derived from RCC. GM-CSF at both concentrations
(500 nmolml-', 1000 nmol ml-') investigated failed to induce
TIL development from RCC specimens when used as single
activator. Also, when GM-CSF was added to tumour/
lymphocyte suspensions together with suboptimal concentra-
tions of IL-2 (8, 40 U ml-'), no TIL development was
observed. Only when the primary cell cultures were sup-
plmented with GM-CSF and concentrations of IL-2
(400 U ml-') which sufficed alone for the activation and
expansion of TILs was TIL development observed. Thus,
GM-CSF cannot be asumed to be an independent growth
factor for TILs derived from RCC, nor does GM-CSF
facilitate the development of TILs when suboptimal doses of
IL-2 are used.
However, TILs activated with GM-CSF and IL-2 differ
signifiantly, in terms of proliferation, expansion and in vitro
kilng behaviour, from TILs activated with EL-2 alone. TILs
grown with GM-CSF + IL-2 proliferated better than TILs
activated with IL-2 alone, but the possible culture period was
not affected. This enhancement ofproliferation, coupled with
similar time periods for which TILs could be maintained in
culture, resulted in a snificantly higher and more rapid
expansion for TILs grown with either 500 umol ml-' or
1000 umol ml-' GM-CSF and IL-2. These results are in good
agreement with the limited data available for peripheral T
cells. Santoli et al. (1988) have demonstrated that GM-CSF
enhances the short-term responsiveness of peripheral T cells
to IL-2, and GM-CSF also potentiates the long-term growth
of non-activated human lymphocytes and of lectin- and Ag-
activated T cells in the presence of IL-2. Although in clnical
investigations the number of activated cells reinfused to the
patients and the effectiveness of treatment demonstrates no
correlation thus far, most dinical protocols require the
expansion of TIL cultures to at kast 1 x 109 to 1 x 101" cls.
Such cell counts are usually reached within 4-6 weeks of
culture (Rosenberg et al., 1988). Thus, this higher prolifera-
tion rate of TILs resulting in high cell counts when GM-
CSF + IL-2 are used for activation would shorten the culture
period, allowing an earlier onset of adoptive immunotherapy
after surgical removal of the primary tumour.
Unlike TILs derived from melanoma (Itoh et al., 1986;
Muul et al., 1987), the killing behaviour of TlLs derived
from RCC is non-specific in general, yet certain clones of
RCC TILs have been isolated and exert autologous tumour-
specific cytotoxicity (Koo et al., 1991; Schendel et al., 1993).
TILs activated with GM-CSF and IL-2 showed a different
killing behaviour in vitro when compared with the corres-
ponding TIL cultures activated with IL-2 alone. The addition
of GM-CSF to the culture medium resulted in enhanced
killng of the autologous tumour target and the allogeneic
renal tumour target. In contrast, lysis of the NK-sensitive
K562 erythroleukaemia cell line and the NK-reistant Daudi
lymphoma cell line ained unaffected. The percentag of
CD3+, CD3+/CD56+, CD4+ and CD8+ cells were similar in
all TIL populations independent of the culture condition.
The higher percentage of cells positive for the NK marker
CD56 in TIL populations cultured with high concentrations
of GM-CSF and IL-2 appears not to be responsible for the
demonstrated enhanced kIilling, since TIL cultures supp-
lmented with the lower concentration of GM-CSF also
showed enhanced klling and a similar percentage of these
cells were CD56+ when compared with TILs activated with
IL-2. Furthrmore, the killing activity against the NK-
senstive K562 cell hne rained uaffected independent of
the concentration of GM-CSF used. The differences in the
pattern of target lysis between TEL populations activated
with IL-2 or GM-CSF + IL-2 were maintained over time in
our experiments. Despite this oflytic activity of
the autolgous tumour target the killing behaviour of the
tested TIL populations was always non-specific as the
allogeneic targets were always lysed equally well or better.
However, the fact remains that GM-CSF is able to enhance
the lytic activity of RCC TILs against renal targets only.
These data are in part imilar to findin rding the ability
of GM-CSF to induce LAK-cell activity in peripheral Iym-
phocytes. Masucci et al. (1990) demonstrated that p l
lymphocytes activated with IL-2 and GM-CSF lysed Daudi
cells and the human colorectal caer cell line SW918
signcntly better than IL-2-activated LAK cels In that
study, a 10-fold lower dose of IL-2 was required when GM-
CSF was added as compared with IL-2 alone to generate a
cytotoxic cell population with the same lytic activity. The
authors asumed that GM-CSF might render more cells
susceptible to IL-2 stimulation, since a higher cell fraction
expraessi CD25 when stimulated with IL-2 and GM-CSF.
However, this is not rlted in our results, since the expres-
sion of CD25 in RCC TILs was similar whether or not
GM-CSF was added to the medium.
The mode of action ofGM-CSFs activity on lymphocytes
in general and TILs in particular remains to be elucidated.
Although the presence of a specific receptor might be
assumed and the murine receptor specific for GM-CSF has
been demonsta in two cell ines of T-lymphoyte origin
(Park et al., 1986), the presence of the GM-CSF receptor on
human lymphocytes has not been thoroughly investigated
and has not as yet been demonsta (Gasson, 1991). We
were not able to demonstrate the presei c of receptors
secific for GM-CSF on the surface of mature RCC TILs.
Although the expression of low nmmbers of the GM-CSF
receptor on a minor subfraction of the TIL populations
invesited might have been undetectable with the ligand-
bindng assay used, the pathway through which GM-CSF
modulates T-cell actions, or at least TIL actions, appears to
be an indiret rather than a direct one. After tumour process-
ing the singkl l suspensions also contain macrphages and
other mononuclear cells. Since GM-CSF has been shown to
activate M opges to enhance non-specific and specific
immune reonses tgainst tumour cells, it might be
speculated that one of these indirect effects could be the
activation and stimulaton ofcells other than lymphocytes to
reles cytokines with T-cell-activating propertes
In summary, GM-CSF is not able to induce TIL develop-
ment from RCC or to facitate TIL activation induced by
IL-2. However, TILs from RCC cultured with IL-2 and
GM-CSF demonstrate snificantly higher proliferation, re-
sulting in a higher expansion of TIL cultures, and exert a
higher killing activity against renal tumour targets in vitro.
These findings provide a rational basis for the use of GM-
CSF in the expansion of TILs, and further investigations are
warranted. Clinical experience with systemic GM-CSF is
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more or less lhimted to the us of this cytokie to shorten
chemotherapy-induced leucpenia. Unlike sysemic IL-2
administration, GM-CSF application is rarely associated with
serious sideeffcts (Morstyn et al., 1988; Horn et al., 1991;
Steger et al., 1992). Based on our results and the known
properts of GM-CSF in improving host defence in
immunooompromised patients by means of enhancd cyto-
kine release and enhancement of cytolytic activity of neut-
rophils, eonnophils and macrophages (Weisbart, 1989), one
might also speculate that GM-CSF could be of therapeutic
value when admin lly to patints reciving
IL-2-based adoptive immunotherapy with TLs. The mode of
action of GM-CSF in enhancing T-cell-mediated cytotoxic
effects is not completely understood. Further in vitro and in
vivo investigations with TILs and GM-CSF are needed to
elucidate these issues.
GG Steger is a 1991 Max Kade Foundation grant reipient
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